Potential Impairment of Hypoglycemic Control Associated with Drug Interactions: A Look at Closer Management Needs for Diabetes Mellitus

M Gossell-Williams1*, J Williams-Johnson2 and S Mc Leary1

1Department of Basic Medical Sciences, University of the West Indies, Mona Campus, Jamaica
2Department of Surgery University of the West Indies, Mona Campus, Jamaica

Abstract

Objectives: One of the main adverse drug reactions presenting to emergency departments is drug induced hypoglycemia in diabetes mellitus patients. The aim of this study was to determine factors, other than lack of compliance with dietary requirements that could be increasing the risk of hypoglycemia among these patients.

Methods: A prospective, observational study was conducted from September 2009 to January 2010 collecting information on all diabetes mellitus patients confirmed to be experiencing hypoglycemia presenting to the Accident and Emergency Department of The University Hospital of the West Indies. Data collected included name of drug implicated and co-administered drug information. Compliance with drug therapy was confirmed. Pubmed search conducted identified peered review papers providing evidence of drug interactions established to increase risk of hypoglycemia.

Results: Eighteen patients were identified for the time period. Most patients (72.2%) were 65 years and older and most (66.7%) were also taking co-administered drugs. A total of 37 combinations in 12 of the patients known to potentiate hypoglycemia were identified. These included aspirin (13 cases), angiotensin converting enzyme inhibitors (12 cases) and beta-adrenoreceptor blockers (8 cases).

Conclusions: Most of the patients presenting with drug induced hypoglycemia were at increased risk of experiencing this adverse event from their prescribed drug combinations. Therefore drug induced hypoglycemia in patients on antidiabetic therapy may not only be associated with non-compliance and patient assessment should review the risk of the combination to the maintenance of glycemic control.

The significant finding of the study: Most of the diabetes mellitus patients presenting with drug induced hypoglycemia (66.7%) were on drug combinations with increased risk of this adverse drug reaction. This study provides evidence of a need for physicians to have easy access to drug interaction information that can facilitate assessment of risk to glycaemic control in diabetic mellitus patients.

Keywords: Adverse drug reaction; Antidiabetic; Drug interactions hypoglycemia

Introduction

Hypoglycemia in patients with diabetes mellitus is a common occurrence and has been established to negatively impact their quality of life [1]. It may be as a result of the hypoglycemic drug therapy and is usually related to noncompliance issues, such as inadequate food intake. It is also well established that the risk of hypoglycemia among patients with diabetes mellitus is increased with the presence of other comorbidities, as well as concomitant administration of other drug therapy. Drug interactions that increase the risk of hypoglycemia can be through pharmacokinetic mechanisms, such as inhibition of drug metabolism or through pharmacodynamic mechanisms, such as increase β-cell function; the impact of these interactions may require dose adjustments [2].

Previous reports from the Accident and Emergency Department (AED) of the University Hospital of the West Indies identified hypoglycemic episodes as the most common adverse drug reaction presenting to the Department [3], thus highlighting a need for further assessment of the possible causes. This report was therefore aimed at identifying possible drug combinations that may account for hypoglycemic episodes in diabetes mellitus patients presenting to the AED.

Methods

A prospective, observational study was conducted in patients seen at the AED of the University of the West Indies.

Hospital from September 2009 to January 2010. AED logbook was the source of identification of all diabetes mellitus patients experiencing hypoglycemia and one senior consultant evaluated the patient medical records to help confirm presentation was associated with drug-induced hypoglycemia, as well as to confirm compliance with drug dosage instructions. The study protocol was approved by the UHWI/UWI/FMS Ethics Committee.

Data collected from the logbook, supported by patient docket included age, gender; name of drug implicated in the hypoglycemic episode and co-administered drug information. Direct patient communication was performed where necessary.

PubMed search identified peered review papers providing evidence of drug interactions established to increase risk of hypoglycemia in persons with diabetes mellitus [4-11]. This information facilitated...
Most of the patients (16 of 18, 88.9%) were also taking drugs prescribed for other comorbidities. In total there were 104 pairs of drug combination involving one antidiabetic drug. Values in columns represent number of patients in study taking individual combinations and the mechanism of the increased risk.

**Table 2: Drug combinations known to increase risk of hypoglycemia when combined with antidiabetic drug.**

| Drug combinations | Sulphonylureas | Insulin | Metformin | Total | Interaction likely to facilitate hypoglycemia |
|-------------------|----------------|---------|-----------|-------|---------------------------------------------|
| Aspirin           | 7              | 1       | 5         | 13    | Promotes insulin secretion and sulphonylurea availability [7,8,11]. |
| Captopril         | 0              | 1       | 1         | 2     |                                                   |
| Enalapril         | 3              | 0       | 3         | 6     | Promotes sensitivity to insulin [5,7,11].         |
| Lisinopril        | 4              | 0       | 2         | 6     |                                                   |
| Carvedilol        | 3              | 0       | 1         | 4     | Inhibit the adrenergic response to hypoglycemia [5,9,11]. |
| Propranolol       | 1              | 0       | 1         | 2     | Promotes insulin secretion and sulphonylurea availability [7,11]. |
| Indomethacin      | 1              | 0       | 1         | 2     |                                                   |
| Ranitidine        | 2              | 0       | 0         | 2     | Increases the bioavailability of sulphonylureas [4, 10]. |

Table 1 lists all the prescription drugs the patients were currently taking; sulphonylureas were the most common antidiabetic drugs. Most of the patients (16 of 18, 88.9%) were also taking drugs prescribed for other comorbidities.

In total there were 104 pairs of drug combination involving one antidiabetic drug and a drug for another indication.

There were 12 patients (66.7%) taking drugs known to potentiate hypoglycemia when combined with antidiabetic drug. Table 2 lists the combinations which have been established to increase potential risk of hypoglycemia. The total number of potential drug interactions with increase risk of hypoglycemia was 37 of the 104 pairs (35.5%) with the co-administration of aspirin presenting as the most common offending drug (13 of 37).

**Discussion**

Maintaining glycemic control without inducing episodes of hypoglycemia is critical in reducing progressive complication with diabetes mellitus, including the risk of cardiovascular disease and death [12-15]. It was previously established that hypoglycemia was the most commonly presenting drug related complication to AED at University Hospital of the West Indies [3] and therefore required further investigation of the possible risk factors that could be pre-disposing diabetes mellitus patients to this complication, as well as intervention to improve patient management.

Most of diabetes mellitus patients admitted to AED with hypoglycemic symptoms during the time period followed were elderly, a factor well known to increase the risk of hypoglycemia [16] and also highlighted by the clinical guidelines for management of diabetes mellitus patients adopted by the Caribbean Health Research Council (CHRC) (http://www.chrc-caribbean.org/files/Pocket%20/Diabetes%20Guidelines%20-%20Pocket%20Edition.pdf).

Most were also taking drugs prescribed for other conditions and thus were predisposed to likely drug interactions. Using drug interactions based on previous reports from review of clinical studies and an understanding of pharmacologic mechanisms of the drugs involved, thirty seven combinations were identified as being able to potentiate hypoglycemia. These included beta receptor blockers (e.g. propranolol), aspirin, indomethacin and angiotensin converting enzyme inhibitors (enalapril, lisonopril, and captopril). The mechanism associated with the increase hypoglycemic potential of the drug combinations include stimulating secretion of insulin (reported with aspirin and indomethacin), blocking adrenergic mediated glycogenolysis (reported with beta-blockers), displacing sulphonylureas from plasma proteins and increasing their risk of hypoglycemia.

**Table 1: List of drug taken by patients at the time of presentation to AED.**

| Drug                        | Frequency |
|-----------------------------|-----------|
| Antidiabetics               |           |
| Acarbose                    | 1         |
| Glibenclamide               | 4         |
| Gliclazide                  | 4         |
| Glimepride                  | 1         |
| Glipizide                   | 2         |
| Glyburide                   | 3         |
| Insulin                     | 6         |
| Metformin                   | 12        |
| Cardiovascular              |           |
| Aspirin                     | 6         |
| Atenolol                    | 1         |
| Captopril                   | 1         |
| Carvedilol                  | 2         |
| Digoxin                     | 1         |
| Enalapril                   | 5         |
| Frusemide                   | 5         |
| Hydrochlorothiazide         | 2         |
| Hydralazine                 | 2         |
| Lisonopril                  | 2         |
| Nifedipine                  | 1         |
| Pentoxifylline              | 2         |
| Propanolol                  | 1         |
| Simvastatin                 | 1         |
| Slow K                      | 2         |
| Spironolactone              | 1         |
| CNS                         |           |
| Benzotropine                | 1         |
| Chlorpromazine              | 1         |
| Haloperidol                 | 1         |
| Others                      |           |
| Bropheniramine              | 1         |
| Calcium supplements         | 2         |
| Daflon                      | 3         |
| Indomethacin                | 1         |
| Iron supplements            | 2         |
| Ranitidine                  | 2         |
| Vitamin C                   | 1         |
| Total                       | 83        |
(reported with aspirin and indomethacin) and increasing the oral bioavailability of sulphipyrazone through inhibition of metabolism (reported with ranitidine) [4-11].

Using the drug interaction checker available at www.drugs.com, except for the combination of metformin with aspirin or indomethacin, all other drug combinations were classified as interactions that were moderately clinically significant (defined as combination that should be avoided and used only under special circumstances).

Therefore, consideration must be given to the clinical implications of drug combinations that are known to have added risk of drug induced hypoglycemia when patients present to AED with this complication.

The data collected from this study did not include a full assessment of other risk factors that could have predisposed patients to hypoglycemia, such as non-compliance with dietary guides. While none of the patients reported non-compliance with medication regimen, the researchers did not attempt to check the written instructions provided with medication.

This is the first study to further examine the profile of the patients presenting with hypoglycemic episodes to AED.

Conclusions

The findings support a need for patient assessment to include whether drug combinations require more vigilant monitoring or adjustment to prevent hypoglycemic episodes. Interventions should include educating patients about measures to ensure glycemic control, whether drug combinations require more vigilant monitoring or adjustment to prevent hypoglycemic episodes. Interventions should include educating patients about measures to ensure glycemic control, adjustment to prevent hypoglycemic episodes. Interventions should include educating patients about measures to ensure glycemic control, adjustment to prevent hypoglycemic episodes. Interventions should include educating patients about measures to ensure glycemic control, adjustment to prevent hypoglycemic episodes.

References

1. Williams SA, Pollack MF, Dibonaventura M (2011) Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 91: 363-370.
2. Cheillah A, Burge MR (2004) Hypoglycemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 21: 511-530.
3. Gossell-Williams M, Williams-Johnson J, Francis L (2010) Hypoglycemic complications with diabetes mellitus management: the predominant adverse drug reaction presenting to the Accident and Emergency Department of The University Hospital of the West Indies. West Indian Med J 59: 555-560.
4. Scheen AJ (2005) Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 28: 601-631.
5. Chan JC, Cockram CS, Critchley JA (1996) Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 15: 135-157.
6. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, et al. (1997) Reports of hypoglycemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 44: 513-518.
7. Ben Salem C, Fathallah N, Hmouda H, Bourouai K (2011) Drug-induced hypoglycemia: an update. Drug Saf 34: 21-45.
8. Torella R, Giugliano D, Siniscalchio N, Spamberto S, D’Onofrio F, et al. (1979) Influence of acetylsalicylic acid on plasma glucose, insulin, glucagon, and growth hormone levels following tolbutamide stimulation in man. Metabolism 28: 887-889.
9. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, et al. (1997) Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126: 955-959.
10. Feely J, Collins WC, Cullen M, el Debani AH, MacWalter RS, et al. (1993) Potentiation of the hypoglycemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol 35: 321-323.
11. B Atrehi (2013) Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 9: 155–163.
12. Ray KK, Seshasai SR, Wijesuriya S, Sivakumar R, Nethercott S, et al. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomized controlled trials. Lancet 373: 1765-1772.
13. Eldor R, Raz I (2009) The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain. Rev Diabet Stud 6: 6-12.
14. Schwartz SS, Kohl BA (2010) Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. Mayo Clin Proc 85: S15-26.
15. Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937–942.
16. Whitmer RA, Karter AJ, Yaffe K, Quesenbery CP Jr, Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301: 1565-1572.
17. Deakin TA, Cade JE, Williams R, Greenwood DC (2006) Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med 23: 944–954.
18. Deakin T, McShane CE, Cade JE, Williams RD (2005) Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2: CD003417.